Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients.
When Epstein-Barr virus (EBV) infects B cells in vitro, the result is a proliferating lymphoblast that expresses at least nine latent proteins. It is generally believed that these cells are rigorously controlled in vivo by cytotoxic T cells. Consistent with this, the latently infected cells in the peripheral blood of healthy carriers are not lymphoblasts. Rather, they are resting memory B cells that are probably not subject to direct immunosurveillance by cytotoxic T lymphocytes (CTLs). When patients become immunosuppressed, the viral load increases in the peripheral blood. The expansion of proliferating lymphoblasts due to the suppressed CTL response is believed to account for this increase and is considered to be a major risk factor for posttransplant lymphoproliferative disease (PTLD) and AIDS-associated B cell lymphoma. Here we show that there is an increase in the numbers of latently infected cells in the peripheral blood of immunosuppressed patients. However, the cells are not proliferating lymphoblasts. They are all latently infected, resting, memory B cells-the same population of infected cells found in the blood of healthy carriers. These results are discussed in the context of a model for EBV persistence that explains why PTLD is usually limited to the lymph nodes.
Babcock
G J
GJ
Department of Pathology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Decker
L L
LL
Freeman
R B
RB
Thorley-Lawson
D A
DA
D001402:B-Lymphocytes / Q000821:virology*; D002453:Cell Cycle; D015967:Gene Expression Regulation, Viral; D016679:Genome, Viral; D006566:Herpesviridae Infections / Q000276:immunology / Q000821:virology; D004854:Herpesvirus 4, Human / Q000302:isolation & purification*; D006801:Humans; D007156:Immunologic Memory; D007165:Immunosuppression Therapy; D016483:Lymphoma, AIDS-Related / Q000209:etiology; D008232:Lymphoproliferative Disorders / Q000209:etiology; D015166:Monitoring, Immunologic; D016377:Organ Transplantation / Q000009:adverse effects; D010641:Phenotype; D010957:Plasmids; D014412:Tumor Virus Infections / Q000276:immunology / Q000821:virology; D019562:Viral Load; D014763:Viral Matrix Proteins / Q000096:biosynthesis; D017735:Virus Latency; D014779:Virus Replication
C037662:EBV-associated membrane antigen, Epstein-Barr virus; D014763:Viral Matrix Proteins